Datapoint: Pfizer Completes Seagen Deal

Pfizer last week completed its acquisition of oncology biotech Seagen Inc. The $43 billion deal nets Pfizer Seagen’s antibody-drug conjugate (ADC) technology, expanding its oncology pipeline to 60 programs. “This is a great day for Pfizer, and, more importantly, for people living with cancer, as we bring together the game-changing science and top talent of Seagen and Pfizer to form a leading Oncology organization,” Chris Boshoff, Pfizer’s chief oncology officer said in a press release. Norstella’s Evaluate Pharma projects Seagen’s lymphoma drug Adcetris will be its top-selling product for 2023, bringing in $998 million in global sales. The ADC currently holds covered or better status for 83% of all insured lives under the medical benefit.

SOURCE: MMIT Analytics, as of 12/15/23, and Evaluate Pharma

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 20

Datapoint: Ipsen’s Latest Accelerated Approval Will Challenge Intercept’s Ocaliva

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 18

Datapoint: Texas Won’t Halt Latest Medicaid Awards

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 17

Datapoint: Oscar Plans to Double Enrollment by 2027

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today